Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

November 27, 2015 1:33 AM ET


Company Overview of EpiVax, Inc.

Company Overview

EpiVax, Inc. is a biotechnology company that engages in the development and implementation of computational immunology tools. It provides interactive protein screening and reengineering interface for Web-based immunogenicity screening; and pre-deimmunization of a functional therapeutic report that is a concise description of a protein therapeutic candidate’s immunogenic potential. The company also offers EpiMatrix high throughput antibody immunogenicity prediction report that gives an overall assessment of potential clinical immunogenicity for a large set of antibody candidates; and Chinese hamster ovary protein predicted immunogenicity, an informatics tool to assess the immunogenic risk of ...

146 Clifford Street

Providence, RI 02903

United States

Founded in 1998





Key Executives for EpiVax, Inc.

Founder, Chief Executive Officer and Chief Scientific Officer
Chief Operating Officer and Chief Information Officer
Managing Director
Head of Marketing and Business Development
Director of Molecular Immunology
Compensation as of Fiscal Year 2015.

EpiVax, Inc. Key Developments

Ipsen and EpiVax, Inc. Collaborate to Produce Next Generation Botulinum Toxins

Ipsen and EpiVax, Inc. announced that they have completed a collaborative project that provides a novel approach for creating next generation botulinum neurotoxin (BoNT) and Targeted Secretion Inhibitor (TSI) therapeutics. Ipsen is actively developing an innovative platform of novel neurotoxin derived therapeutics, including TSI, that is opening up new therapeutic opportunities to address various medical conditions with unmet need. EpiVax will move the program forward, continuing potential product development for clinical use in neuromuscular health and aesthetic treatments. EpiVax will present the results of the research program so far conducted at the upcoming IBRCC 2015 conference on botulinum neurotoxins, in Frederick, Maryland. EpiVax applied its proprietary T cell epitope modification technology ISPRI to generate an engineered BoNT sequence. This platform program employs two key technologies developed and perfected by EpiVax: deimmunization and tolerization.

EpiVax, Inc. Presents at BIO-Europe 2015, Nov-02-2015

EpiVax, Inc. Presents at BIO-Europe 2015, Nov-02-2015 . Venue: Munich, Germany.

EpiVax, Inc. Presents at BIO-Europe Spring 2015, Mar-09-2015

EpiVax, Inc. Presents at BIO-Europe Spring 2015, Mar-09-2015 . Venue: Paris Expo - Porte de Versailles, Hall 5, Paris, France.

Similar Private Companies By Industry

Company Name Region
Tepha, Inc. United States
Ekteino Laboratories, Inc. United States
Exemplar Genetics LLC United States
Alector LLC United States
Diogenics United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact EpiVax, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at